Sarepta (SRPT) skyrockets 35% on Morgan Stanley PT hike, stellar trial results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by ...
24/7 Wall St.

Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?

Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...
Las Vegas Sun

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...
Mena FN

Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead The Charge In Pioneering New Treatments Delveinsight

DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...
MedPage Today

Investigational FSHD Drug Did Little to Change DUX4 Expression

The investigational drug losmapimod did not significantly change expression of the gene behind facioscapulohumeral muscular dystrophy (FSHD), but it was associated with potential improvements in ...